Targeting High Dynamin-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Dynamin-2 (DNM2) is a GTPase crucial for cellular processes like endocytosis and cytokinesis.
• DNM2 mutations are implicated in T-cell precursor acute lymphoblastic leukemia (ALL).
• DNM2 expression patterns in adult B-cell and T-cell ALL remain largely uncharacterized.

Purpose of the Study:

• To investigate DNM2 mRNA expression levels in adult B-cell and T-cell ALL.
• To explore the relationship between DNM2 expression and clinical features, outcomes, and leukemia cell proliferation.
• To elucidate the regulatory mechanisms of DNM2 expression involving Ikaros and casein kinase-2 (CK2).

Main Methods:

• Quantitative analysis of DNM2 mRNA levels in ALL patient samples compared to normal controls.
• Correlation analysis between DNM2 expression and clinical/laboratory parameters.
• Investigation of Ikaros binding to the DNM2 promoter using molecular biology techniques.
• Assessment of the effects of DNM2 inhibition and CK2 inhibition on leukemia cell proliferation.

Main Results:

• DNM2 is significantly upregulated in both B-cell and T-cell ALL compared to normal controls.
• High DNM2 expression correlates with specific clinical features, poorer outcomes, and increased leukemia cell proliferation.
• Ikaros directly suppresses DNM2 transcription, and IKZF1 deletion is linked to elevated DNM2 levels.
• CK2 inhibition enhances Ikaros function, reducing DNM2 expression, and DNM2 inhibition synergizes with CK2 inhibition to suppress leukemia cell growth.

Conclusions:

• Elevated DNM2 expression is a key feature in adult B- and T-cell ALL, associated with adverse clinical parameters and proliferation.
• Ikaros dysregulation, particularly IKZF1 deletion, contributes to high DNM2 expression in ALL.
• Targeting DNM2 and modulating Ikaros function via CK2 inhibition presents a potential therapeutic strategy for ALL.